Cargando…

Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus

OBJECTIVE: To assess factors associated with primary and secondary non-response to rituximab in systemic lupus erythematosus (SLE) and evaluate management of secondary non-depletion non-response (2NDNR). METHODS: 125 patients with SLE treated with rituximab over 12 years were studied prospectively....

Descripción completa

Detalles Bibliográficos
Autores principales:	Md Yusof, Md Yuzaiful, Shaw, Daniel, El-Sherbiny, Yasser M, Dunn, Emma, Rawstron, Andy C, Emery, Paul, Vital, Edward M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2017
Materias:	Clinical and Epidemiological Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5705851/ https://www.ncbi.nlm.nih.gov/pubmed/28684557 http://dx.doi.org/10.1136/annrheumdis-2017-211191

Ejemplares similares

Biologic Sequencing in Systemic Lupus Erythematosus: After Secondary Non-response to Rituximab, Switching to Humanised Anti-CD20 Agent Is More Effective Than Belimumab
por: Hassan, Sabih Ul, et al.
Publicado: (2020)

A Personalized Rituximab Retreatment Approach Based on Clinical and B-Cell Biomarkers in ANCA-Associated Vasculitis
por: Arnold, Jack, et al.
Publicado: (2022)

Early intervention in systemic lupus erythematosus: time for action to improve outcomes and health-care utilization
por: Md Yusof, Md Yuzaiful, et al.
Publicado: (2021)

Predicting Sustained Clinical Response to Rituximab in Moderate to Severe Systemic Manifestations of Primary Sjögren Syndrome
por: Pepple, Sophanit, et al.
Publicado: (2022)

Responsiveness of clinical and ultrasound outcome measures in musculoskeletal systemic lupus erythematosus
por: Mahmoud, Khaled, et al.
Publicado: (2019)

Prediction of autoimmune connective tissue disease in an at-risk cohort: prognostic value of a novel two-score system for interferon status
por: Md Yusof, Md Yuzaiful, et al.
Publicado: (2018)

B Cell Tetherin: A Flow Cytometric Cell‐Specific Assay for Response to Type I Interferon Predicts Clinical Features and Flares in Systemic Lupus Erythematosus
por: El‐Sherbiny, Yasser M., et al.
Publicado: (2020)

Comprehensive genetic and functional analyses of Fc gamma receptors influence on response to rituximab therapy for autoimmunity
por: Robinson, James I., et al.
Publicado: (2022)

Breakthrough SARS-CoV-2 infections and prediction of moderate-to-severe outcomes during rituximab therapy in patients with rheumatic and musculoskeletal diseases in the UK: a single-centre cohort study
por: Md Yusof, Md Yuzaiful, et al.
Publicado: (2023)

Off-label use of rituximab for systemic lupus erythematosus in Europe
por: Rydén-Aulin, Monica, et al.
Publicado: (2016)

Plucked hair follicles from patients with chronic discoid lupus erythematosus show a disease-specific molecular signature
por: Shalbaf, Mohammad, et al.
Publicado: (2019)

Ultrasound to identify systemic lupus erythematosus patients with musculoskeletal symptoms who respond best to therapy: the US Evaluation For mUsculoskeletal Lupus longitudinal multicentre study
por: Mahmoud, Khaled, et al.
Publicado: (2021)

Cohort profile: systemic lupus erythematosus in Sweden: the Swedish Lupus Linkage (SLINK) cohort
por: Arkema, Elizabeth V, et al.
Publicado: (2015)

Functionally impaired plasmacytoid dendritic cells and non-haematopoietic sources of type I interferon characterize human autoimmunity
por: Psarras, Antonios, et al.
Publicado: (2020)

Real-world incidence and prevalence of systemic lupus erythematosus in Alberta, Canada
por: Fatoye, Francis, et al.
Publicado: (2018)

Rituximab reduces the hospitalization in patients with systemic lupus erythematosus
por: Martínez-Pérez, R, et al.
Publicado: (2010)

Association between organ damage and mortality in systemic lupus erythematosus: a systematic review and meta-analysis
por: Murimi-Worstell, Irene B, et al.
Publicado: (2020)

Coping with systemic lupus erythematosus in patients’ words
por: Cornet, Alain, et al.
Publicado: (2022)

Causes and outcome of hospitalisations in Tunisian patients with systemic lupus erythematosus
por: Jallouli, M, et al.
Publicado: (2014)

Association of patient copayment and medication adherence in systemic lupus erythematosus
por: Lomanto Silva, Raisa, et al.
Publicado: (2023)

Rituximab therapy for juvenile-onset systemic lupus erythematosus
por: Nwobi, Obioma, et al.
Publicado: (2007)

Clinical and histopathological features of myositis in systemic lupus erythematosus
por: Tiniakou, Eleni, et al.
Publicado: (2022)

Risk factors for osteoporosis and fragility fractures in patients with systemic lupus erythematosus
por: Carli, L, et al.
Publicado: (2016)

Systemic lupus erythematosus and neutropaenia: a hallmark of haematological manifestations
por: Meyer, Aurore, et al.
Publicado: (2020)

Development of a systemic lupus erythematosus cardiovascular risk equation
por: Petri, Michelle A, et al.
Publicado: (2019)

Analysis of rituximab’s usage for the treatment of pediatric systemic lupus erythematosus
por: Alves, Alessandra, et al.
Publicado: (2014)

Thrombotic thrombocytopenic purpura treated with rituximab in systemic lupus erythematosus
por: Karimifar, Mansoor
Publicado: (2012)

Rituximab for Remission Induction and Maintenance in Refractory Systemic Lupus Erythematosus
por: Bonilla-Abadía, Fabio, et al.
Publicado: (2014)

Rituximab in the treatment of extensive and refractory subacute cutaneous lupus erythematosus
por: Penha, Mariana Álvares, et al.
Publicado: (2018)

B-cell targeted therapy in systemic lupus erythematosus: potential of rituximab
por: Wiesik-Szewczyk, E, et al.
Publicado: (2012)

Belimumab: a technological advance for systemic lupus erythematosus patients? Report of a systematic review and meta-analysis
por: Kandala, Ngianga-Bakwin, et al.
Publicado: (2013)

Risk of COVID-19 among unvaccinated and vaccinated patients with systemic lupus erythematosus: a general population study
por: Jiang, Xiaofeng, et al.
Publicado: (2023)

Rituximab in Systemic Lupus Erythematosus: Transient Effects on Autoimmunity Associated Lymphocyte Phenotypes and Implications for Immunogenicity
por: Faustini, Francesca, et al.
Publicado: (2022)

Editorial: Advance in B-cell therapies for the treatment of rheumatic and musculoskeletal diseases
por: Md Yusof, Md Yuzaiful, et al.
Publicado: (2022)

Hydroxychloroquine treatment in European patients with lupus erythematosus: dosing, retinopathy screening and adherence
por: Osmani, Zgjim, et al.
Publicado: (2021)

Complement levels and risk of organ involvement in patients with systemic lupus erythematosus
por: Gandino, Ignacio Javier, et al.
Publicado: (2017)

Serum uric acid is associated with damage in patients with systemic lupus erythematosus
por: Elera-Fitzcarrald, Claudia, et al.
Publicado: (2020)

Living with systemic lupus erythematosus in 2020: a European patient survey
por: Cornet, Alain, et al.
Publicado: (2021)

Attribution of cause of end-stage renal disease among patients with systemic lupus erythematosus: the Georgia Lupus Registry
por: Plantinga, Laura C, et al.
Publicado: (2016)

Predictors of persistent disease activity and long quiescence in systemic lupus erythematosus: results from the Hopkins Lupus Cohort
por: Giannakou, Ioanna, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_p6bid4mdftdsc7mngvn1u4s72n